China Looks To Raise Standards As Pharma Ties Up With Large Distributors And Retailers
This article was originally published in PharmAsia News
Executive Summary
Pfizer’s RMB 800 million ($127 million) of annual retail pharmacy sales in China shows the growing potential of the retail channel, and regulators are taking note.
You may also be interested in...
Pfizer Teams With Distributor Jointown To Delve Deeper Into China's Rural Markets
SHANGHAI - Pfizer Inc., like many of its Big Pharma peers is seeking out local Chinese partners to gain access to China's lower-tier cities and rural areas. To that end, the world's largest pharma company recently signed an agreement with China's third-largest pharma distributor Jointown Pharmaceutical Group Co., Ltd. to distribute Pfizer products in markets outside of big cities
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.